All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Aura Biosciences Inc., a company developing a virus-like drug conjugate (VDC) for the potential treatment of a type of rare ocular cancer, has closed an oversubscribed $80 million financing.
